CIK 0001425205
- Accelerated filer
IOVANCE BIOTHERAPEUTICS, INC.
Sign in to watch- Ticker
- IOVA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 753254381
- Phone
- +1 650-260-7120
- Business address
- 825 INDUSTRIAL ROAD, 4TH FLOOR, SAN CARLOS, CA, 94070
- Former names
- Lion Biotechnologies, Inc., Genesis Biopharma, Inc, FREIGHT MANAGEMENT CORP
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 99 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-06-10 | Countouriotis Athena Director | Grant or award · Deferred Restricted Stock Unit | +51,204 | 51,204 | ||
| 2022-06-10 | MCPEAK MERRILL A Director | Grant or award · Deferred Restricted Stock Unit | +51,204 | 51,204 | ||
| 2022-06-10 | Maynard Ryan D Director | Grant or award · Deferred Restricted Stock Unit | +51,204 | 51,204 | ||
| 2022-06-10 | WEISER MICHAEL Director | Grant or award · Deferred Restricted Stock Unit | +51,204 | 51,204 | ||
| 2022-06-10 | Dukes Iain D. Director | Grant or award · Deferred Restricted Stock Unit | +102,409 | 102,409 | ||
| 2022-06-10 | DIXON WENDY L Director | Grant or award · Deferred Restricted Stock Unit | +51,204 | 51,204 | ||
| 2022-06-01 | Vogt Frederick G Interim CEO & General Counsel | Purchase | +1,000 | $6.44 | $6K | 1,000 |
| 2022-06-01 | Rothbaum Wayne P. Director | Purchase | +500,000 | $6.43 | $3.2M | 8,067,333 |
| 2022-05-31 | MCPEAK MERRILL A Director | Purchase | +10,000 | $6.84 | $68K | 20,150 |
| 2022-05-31 | MCPEAK MERRILL A Director | Purchase | +10,000 | $6.80 | $68K | 218,633 |
| 2022-05-31 | Maynard Ryan D Director | Purchase | +7,500 | $6.75 | $51K | 7,500 |
| 2022-05-31 | WEISER MICHAEL Director | Purchase | +2,187 | $6.79 | $15K | 104,819 |
| 2022-05-31 | WEISER MICHAEL Director | Purchase | +7,813 | $6.80 | $53K | 112,632 |
| 2022-05-31 | Rothbaum Wayne P. Director | Purchase | +500,000 | $6.77 | $3.4M | 7,567,333 |
| 2022-01-14 | Vogt Frederick G Interim CEO & General Counsel | Grant or award · Restricted Stock Units | +250,000 | 250,000 | ||
| 2022-01-14 | GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer | Grant or award · Restricted Stock Units | +33,750 | 33,750 | ||
| 2022-01-14 | GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer | Grant or award · Stock Option (right to buy) | +67,500 | 67,500 | ||
| 2022-01-14 | BILINSKY IGOR Chief Operating Officer | Grant or award · Restricted Stock Units | +33,750 | 33,750 | ||
| 2022-01-14 | BILINSKY IGOR Chief Operating Officer | Grant or award · Stock Option (right to buy) | +67,500 | 67,500 | ||
| 2022-01-14 | Bellemin Jean-Marc Chief Financial Officer | Grant or award · Stock Option (right to buy) | +135,000 | 135,000 |
Page 21 of 23 · 446 trades